Literature DB >> 19463394

Reperfusion in patients with renal dysfunction after presentation with ST-segment elevation or left bundle branch block: GRACE (Global Registry of Acute Coronary Events).

Caroline Medi1, Gilles Montalescot, Andrzej Budaj, Keith A A Fox, José López-Sendón, Gordon FitzGerald, David B Brieger.   

Abstract

OBJECTIVES: We investigated the relative benefit of reperfusion strategies in renal dysfunction and ST-segment elevation/left bundle branch block (STE/LBBB).
BACKGROUND: Few data are available informing the treatment of STE myocardial infarction in the presence of renal dysfunction.
METHODS: Patients (N = 12,532) from the GRACE (Global Registry of Acute Coronary Events) presenting with STE/LBBB were stratified by renal function and receipt of fibrinolysis, primary percutaneous coronary intervention (PCI), or neither.
RESULTS: As renal function declined, hospital mortality increased and reperfusion decreased (both p < 0.001). Compared with no reperfusion, primary PCI was associated with lower hospital mortality in patients with normal renal function (1.9% vs. 3.7%, p = 0.001, adjusted) but no reduction in those with renal dysfunction (14% vs. 15% for glomerular filtration rate [GFR] 30 to 59 ml/min/1.73 m(2); 29% vs. 32% for GFR <30 ml/min/1.73 m(2)). Fibrinolysis was not associated with lower hospital mortality for normal (3.1% vs. 3.7%, p = NS) or low renal function (32% vs. 32%, p = NS) and with higher mortality with moderate renal dysfunction (adjusted odds ratio: 1.35, 95% confidence interval: 1.01 to 1.80). Primary PCI was associated with increased hospital bleeding and fibrinolysis with increased stroke in all patients. Among hospital survivors, primary PCI, but not fibrinolysis, was associated with lower mortality for moderate dysfunction. Both reperfusion strategies were associated with higher mortality for severe dysfunction.
CONCLUSIONS: In STE/LBBB and renal dysfunction, mortality rates are high and reperfusion rates are lower. In moderate renal dysfunction, primary PCI is associated with mortality reduction at 6 months. Outcomes remain poor with severe renal dysfunction, despite receipt of reperfusion therapy.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19463394     DOI: 10.1016/j.jcin.2008.09.010

Source DB:  PubMed          Journal:  JACC Cardiovasc Interv        ISSN: 1936-8798            Impact factor:   11.195


  22 in total

1.  Chronic kidney disease and risk for coronary events: value of myocardial perfusion imaging.

Authors:  George A Beller
Journal:  J Nucl Cardiol       Date:  2010-10       Impact factor: 5.952

2.  Effect of late revascularization of a totally occluded coronary artery after myocardial infarction on mortality rates in patients with renal impairment.

Authors:  Ramin S Hastings; Judith S Hochman; Vladimir Dzavik; Gervasio A Lamas; Sandra A Forman; Francois Schiele; Lampros K Michalis; Dimitris Nikas; Joanna Jaroch; Harmony R Reynolds
Journal:  Am J Cardiol       Date:  2012-06-22       Impact factor: 2.778

3.  Predictors of 1-year mortality in patients with contemporary guideline-adherent therapy after acute myocardial infarction: results from the OMEGA study.

Authors:  Spyridon Liosis; Timm Bauer; Rudolf Schiele; Helmut Gohlke; Martin Gottwik; Hugo Katus; Georg Sabin; Ralf Zahn; Steffen Schneider; Bernhard Rauch; Jochen Senges; Uwe Zeymer
Journal:  Clin Res Cardiol       Date:  2013-06-06       Impact factor: 5.460

Review 4.  Chronic kidney disease in acute coronary syndromes.

Authors:  Giancarlo Marenzi; Angelo Cabiati; Emilio Assanelli
Journal:  World J Nephrol       Date:  2012-10-06

5.  The Effect of Admission Renal Function on the Treatment and Outcome of Patients with Acute Coronary Syndrome.

Authors:  Zach Rozenbaum; Sydney Benchetrit; Saar Minha; Yoram Neuman; Meital Shlezinger; Ilan Goldenberg; Morris Mosseri; David Pereg
Journal:  Cardiorenal Med       Date:  2017-02-17       Impact factor: 2.041

Review 6.  How to balance risks and benefits in the management of CKD patients with coronary artery disease.

Authors:  Giancarlo Marenzi; Nicola Cosentino; Carlo Guastoni
Journal:  J Nephrol       Date:  2015-02-25       Impact factor: 3.902

Review 7.  Recent advances in the diagnosis and treatment of acute myocardial infarction.

Authors:  Koushik Reddy; Asma Khaliq; Robert J Henning
Journal:  World J Cardiol       Date:  2015-05-26

8.  The impact of stage of chronic kidney disease on the outcomes of diabetics with acute myocardial infarction treated with percutaneous coronary intervention.

Authors:  Teodora Vichova; Jiri Knot; Jaroslav Ulman; Marek Maly; Zuzana Motovska
Journal:  Int Urol Nephrol       Date:  2016-03-19       Impact factor: 2.370

9.  Clinical outcomes after percutaneous coronary intervention in non-dialysis patients with acute coronary syndrome and advanced renal dysfunction.

Authors:  Yusuke Uemura; Shinji Ishikawa; Kenji Takemoto; Yosuke Negishi; Akihito Tanaka; Kensuke Takagi; Naoyuki Yoshioka; Norio Umemoto; Yosuke Inoue; Itsuro Morishima; Naoki Shibata; Hiroshi Asano; Hideki Ishii; Masato Watarai; Toyoaki Murohara
Journal:  Clin Exp Nephrol       Date:  2020-01-06       Impact factor: 2.801

10.  Postangiography Increases in Serum Creatinine and Biomarkers of Injury and Repair.

Authors:  Caroline Liu; Maria K Mor; Paul M Palevsky; James S Kaufman; Heather Thiessen Philbrook; Steven D Weisbord; Chirag R Parikh
Journal:  Clin J Am Soc Nephrol       Date:  2020-08-24       Impact factor: 8.237

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.